These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1206 related items for PubMed ID: 22907761

  • 1. Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: a post hoc, pooled analysis from two placebo-controlled trials.
    DuBeau CE, Morrow JD, Kraus SR, Creanga D, Bavendam T.
    Neurourol Urodyn; 2012 Nov; 31(8):1258-65. PubMed ID: 22907761
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder.
    Ginsberg D, Schneider T, Kelleher C, Van Kerrebroeck P, Swift S, Creanga D, Martire DL.
    BJU Int; 2013 Aug; 112(3):373-85. PubMed ID: 23826844
    [Abstract] [Full Text] [Related]

  • 3. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial.
    Herschorn S, Swift S, Guan Z, Carlsson M, Morrow JD, Brodsky M, Gong J.
    BJU Int; 2010 Jan; 105(1):58-66. PubMed ID: 20132103
    [Abstract] [Full Text] [Related]

  • 4. Comparison of fesoterodine and tolterodine in patients with overactive bladder.
    Chapple CR, Van Kerrebroeck PE, Jünemann KP, Wang JT, Brodsky M.
    BJU Int; 2008 Nov; 102(9):1128-32. PubMed ID: 18647298
    [Abstract] [Full Text] [Related]

  • 5. Superiority of fesoterodine 8 mg vs 4 mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial.
    Chapple C, Schneider T, Haab F, Sun F, Whelan L, Scholfield D, Dragon E, Mangan E.
    BJU Int; 2014 Sep; 114(3):418-26. PubMed ID: 24552358
    [Abstract] [Full Text] [Related]

  • 6. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence.
    Rogers RG, Bachmann G, Scarpero H, Jumadilova Z, Sun F, Morrow JD, Guan Z, Bavendam T.
    Curr Med Res Opin; 2009 Sep; 25(9):2159-65. PubMed ID: 19601704
    [Abstract] [Full Text] [Related]

  • 7. Tolterodine extended release is efficacious in continent and incontinent subjects with overactive bladder.
    Rovner ES, Rackley R, Nitti VW, Wang JT, Guan Z, 037 Study Group.
    Urology; 2008 Sep; 72(3):488-93. PubMed ID: 18639327
    [Abstract] [Full Text] [Related]

  • 8. Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers.
    Chapple C, Herschorn S, Abrams P, Sun F, Brodsky M, Guan Z.
    Eur Urol; 2009 Sep; 56(3):534-41. PubMed ID: 19070418
    [Abstract] [Full Text] [Related]

  • 9. Relationships between improvements in symptoms and patient assessments of bladder condition, symptom bother and health-related quality of life in patients with overactive bladder treated with tolterodine.
    Coyne KS, Elinoff V, Gordon DA, Deng DY, Brodsky M, Glasser DB, Jumadilova Z, Carlsson M.
    Int J Clin Pract; 2008 Jun; 62(6):925-31. PubMed ID: 18479285
    [Abstract] [Full Text] [Related]

  • 10. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder.
    Chapple C, Van Kerrebroeck P, Tubaro A, Haag-Molkenteller C, Forst HT, Massow U, Wang J, Brodsky M.
    Eur Urol; 2007 Oct; 52(4):1204-12. PubMed ID: 17651893
    [Abstract] [Full Text] [Related]

  • 11. Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms.
    Kaplan SA, Roehrborn CG, Gong J, Sun F, Guan Z.
    BJU Int; 2012 Jun; 109(12):1831-40. PubMed ID: 21966995
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.
    Chancellor MB, Zinner N, Whitmore K, Kobashi K, Snyder JA, Siami P, Karram M, Laramée C, Capo' JP, Seifeldin R, Forero-Schwanhaeuser S, Nandy I.
    Clin Ther; 2008 Oct; 30(10):1766-81. PubMed ID: 19014833
    [Abstract] [Full Text] [Related]

  • 13. Effects of voluntary dose escalation in a placebo-controlled, flexible-dose trial of fesoterodine in subjects with overactive bladder.
    Staskin D, Khullar V, Michel MC, Morrow JD, Sun F, Guan Z, Dmochowski R.
    Neurourol Urodyn; 2011 Nov; 30(8):1480-5. PubMed ID: 21560158
    [Abstract] [Full Text] [Related]

  • 14. Does urodynamic verification of overactive bladder determine treatment success? Results from a randomized placebo-controlled study.
    Malone-Lee JG, Al-Buheissi S.
    BJU Int; 2009 Apr; 103(7):931-7. PubMed ID: 19281469
    [Abstract] [Full Text] [Related]

  • 15. Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial.
    Khullar V, Hill S, Laval KU, Schiøtz HA, Jonas U, Versi E.
    Urology; 2004 Aug; 64(2):269-74; discussion 274-5. PubMed ID: 15302476
    [Abstract] [Full Text] [Related]

  • 16. A randomized double-blind placebo-controlled multicentre study to explore the efficacy and safety of tamsulosin and tolterodine in women with overactive bladder syndrome.
    Robinson D, Cardozo L, Terpstra G, Bolodeoku J, Tamsulosin Study Group.
    BJU Int; 2007 Oct; 100(4):840-5. PubMed ID: 17822465
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence.
    Roehrborn CG, Abrams P, Rovner ES, Kaplan SA, Herschorn S, Guan Z.
    BJU Int; 2006 May; 97(5):1003-6. PubMed ID: 16643482
    [Abstract] [Full Text] [Related]

  • 18. Flexible-dose fesoterodine in elderly adults with overactive bladder: results of the randomized, double-blind, placebo-controlled study of fesoterodine in an aging population trial.
    Wagg A, Khullar V, Marschall-Kehrel D, Michel MC, Oelke M, Darekar A, Bitoun CE, Weinstein D, Osterloh I.
    J Am Geriatr Soc; 2013 Feb; 61(2):185-93. PubMed ID: 23350833
    [Abstract] [Full Text] [Related]

  • 19. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score.
    Kaplan SA, Roehrborn CG, Chancellor M, Carlsson M, Bavendam T, Guan Z.
    BJU Int; 2008 Nov; 102(9):1133-9. PubMed ID: 18510659
    [Abstract] [Full Text] [Related]

  • 20. Investigation of the clinical efficacy and safety of pregabalin alone or combined with tolterodine in female subjects with idiopathic overactive bladder.
    Marencak J, Cossons NH, Darekar A, Mills IW.
    Neurourol Urodyn; 2011 Jan; 30(1):75-82. PubMed ID: 20886571
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 61.